PolyPid Reports Q2 2026 Earnings, Highlights FDA Priority Review and Partnership with Azurity
PolyPid (PYPD) reported a net loss of $7.8 million for the second quarter of 2026, down from $10 million in the same period last year. The company also noted reduced losses per share at $0.35 compared to $0.78 in Q2 2025. Over six months, PolyPid’s net loss was $15.6 million versus $18.2 million for the first half of 2025. The company highlighted a partnership with Azurity Pharmaceuticals that has already generated $30 million through milestone payments and could deliver over $290 million in total based on regulatory, launch, and sales milestones. PolyPid also noted it retains manufacturing control while leveraging Azurity’s commercial infrastructure for the U.S. and Canada. PolyPid expects FDA approval of its New Drug Application (NDA) by November 28, 2026, with a projected product launch in early 2027. The company has sufficient cash runway into 2028 based on current resources and anticipated milestone payments.
Tickers: $PYPD